Literature DB >> 7732657

Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides.

I Demirhan1, O Hasselmayer, D Hofmann, A Chandra, F P Svinarchuk, V V Vlassov, J Engels, P Chandra.   

Abstract

We have used an in vitro approach to study the efficiency of antisense oligonucleotides in inhibiting LTR-(HIV-1)-directed CAT expression catalyzed by tat protein, the functional protein of the transactivator gene. We selected the target sequence localized near the 5' end of the tat mRNA. The following conclusions can be drawn from the data presented here: a) Antisense oligonucleotides modified by conjugation of cholesterol at the 3' end have a severalfold higher inhibitory response, b) inhibitory response is dependent on the mode of introducing oligonucleotides, and c) the inhibition by antisense oligonucleotides is sequence specific and directed towards the targeted region. This approach could be useful for targeting functional regions of regulatory gene products and designing gene-targeted inhibitors of virus replication.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7732657     DOI: 10.1007/bf01702654

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  47 in total

1.  Trans-activating rev protein of the human immunodeficiency virus 1 interacts directly and specifically with its target RNA.

Authors:  S Daefler; M E Klotman; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

2.  Characterization of a cDNA clone encoding the visna virus transactivating protein.

Authors:  J L Davis; J E Clements
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

4.  Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element.

Authors:  T Vickers; B F Baker; P D Cook; M Zounes; R W Buckheit; J Germany; D J Ecker
Journal:  Nucleic Acids Res       Date:  1991-06-25       Impact factor: 16.971

5.  Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.

Authors:  J Goodchild; S Agrawal; M P Civeira; P S Sarin; D Sun; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.

Authors:  S Agrawal; J Goodchild; M P Civeira; A H Thornton; P S Sarin; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

Review 7.  Gene therapy for cancer.

Authors:  A A Gutierrez; N R Lemoine; K Sikora
Journal:  Lancet       Date:  1992-03-21       Impact factor: 79.321

8.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.

Authors:  B Ensoli; L Buonaguro; G Barillari; V Fiorelli; R Gendelman; R A Morgan; P Wingfield; R C Gallo
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

9.  Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.

Authors:  M Matsukura; K Shinozuka; G Zon; H Mitsuya; M Reitz; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

10.  Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues.

Authors:  S Agrawal; T Ikeuchi; D Sun; P S Sarin; A Konopka; J Maizel; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.